2. Baseline characteristics of included trials.
| Trial | Intervention | Sample size | Intervention cross‐over | Mean age (year) a | Benign | DCIS component | Invasive cancer | Localization | |||
| Ultrasound | Stereotactic | ||||||||||
| Postma 2012 | ROLL | 162 | 4 | 60.5 ± 7.7 | 0 | 90 | 162 | P = 0.42 | 150 | 13 | — |
| WGL | 152 | 1 | 61.1 ± 9.7 | 0 | 78 | 152 | — | 146 | 7 | — | |
| Ocal 2011 | ROLL | 56 | 0 | 45 (25 to 61) | 44 | 6 | 6 | P = 0.505 | 31 | 25 | P = 0.13 |
| WGL | 52 | 0 | 47 (34 to 72) | 38 | 7 | 7 | — | 21 | 31 | — | |
| Mariscal Martinez 2009 | ROLL | 66 | 0 | 57.5 ± 10.5 | 0 | 10 | 56 | — | 45 | 21 | P = 0.102 |
| WGL | 68 | 0 | 56.4 ± 11.7 | 0 | 14 | 54 | — | 37 | 31 | — | |
| Moreno 2008 | ROLL | 61 | 0 | 50.7 (32 to 76) | 51 | 8 | 2 | P = 0.047 | 24 | 27 | P = 0.13 |
| WGL | 59 | 0 | 49.9 (35 to 77) | 43 | 10 | 6 | — | 28 | 31 | — | |
| Medina‐Franco 2008 | ROLL | 50 | 0 | 55.8 ± 9.3 | — | — | 9 | P = 0.79 | 9 | 41 | P = 0.43 |
| WGL | 50 | 0 | 55.3 ± 10.24 | — | — | 8 | — | 11 | 39 | — | |
| Rampaul 2004 | ROLL | 48 | 2 | — | 9 | 13 | 26 | — | 24 | 24 | — |
| WGL | 47 | 0 | — | 8 | 12 | 27 | — | 21 | 26 | — | |
| Lovrics 2011a | RSL | 152 | 18 | 60.9 ± 9.5 | 0 | 30 | 124 | — | 107 | 45 | — |
| WGL | 153 | 0 | 59.9 ± 10.4 | 0 | 24 | 129 | — | 106 | 47 | — | |
| Gray 2001 | RSL | 51 | 0 | — | 16 | 4 | 31 | — | — | — | — |
| WGL | 46 | 0 | — | 20 | 5 | 21 | — | — | — | — | |
DCIS: ductal carcinoma in situ ROLL: radioguided occult lesion localization RSL: radioactive seed localization WGL: wire guided localization
aResults expressed either in ± SD or (range).